Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2025)

Historic FCF Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 18.29%.

  • Kiniksa Pharmaceuticals International's FCF Margin rose 203000.0% to 18.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.03%, marking a year-over-year increase of 141700.0%. This contributed to the annual value of 6.0% for FY2024, which is 11300.0% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's FCF Margin is 18.29%, which was up 203000.0% from 17.76% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's FCF Margin ranged from a high of 62.57% in Q3 2022 and a low of 504.18% during Q2 2021
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median FCF Margin value was 4.78% (recorded in 2024), while the average stood at 45.79%.
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 4751700bps in 2022, then tumbled by -372600bps in 2023.
  • Kiniksa Pharmaceuticals International's FCF Margin (Quarter) stood at 102.08% in 2021, then surged by 108bps to 7.78% in 2022, then plummeted by -34bps to 5.12% in 2023, then surged by 198bps to 15.26% in 2024, then rose by 20bps to 18.29% in 2025.
  • Its FCF Margin was 18.29% in Q3 2025, compared to 17.76% in Q2 2025 and 16.13% in Q1 2025.